Selective Degradation of FGFR1/2 Overcomes Antiestrogen Resistance in ER⁺ Breast Cancer with FGFR1/2 Alterations

Researchers investigated the selective degradation of FGFR1/2 using the proteolysis-targeting chimera DGY-09-192 as a novel therapeutic strategy in ER+ breast cancers harboring FGFR1/2 somatic alterations.